WCYN, VCMG, BRGO, TRMD, PSDV, IDOI
Our Stocks to Watch today include West Canyon Energy Corp. (OTC: WCYN), Veracity Management Global Inc. (OTCBB: VCMG), Bergio International Inc. (OTCBB: BRGO), TORM (Nasdaq: TRMD), pSivida Corp. (Nasdaq: PSDV) and IDO Security Inc. (OTCBB: IDOI).
WEST CANYON ENERGY CORPORATION (OTC: WCYN)
"Up 259.37% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/WCYN.php
West Canyon Energy Corp., an exploration stage company, engages in the exploration and production of oil and gas properties in Colombia. It primarily owns a 16% participation stake in the Buenavista Block, an exploration project located northeast of Bogota, Colombia. The company was formerly known as PetroSouth Energy Corp. and changed its name to West Canyon Energy Corp. in April 2008. West Canyon Energy Corp. was founded in 2004 and is based in Houston, Texas.
No recent news for West Canyon Energy Corp. (OTC: WCYN).
VERACITY MANAGEMENT GLOBAL INCORPORATED (OTCBB: VCMG)
"Up 180.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/VCMG.php
Veracity Management Global, Inc. does not have significant operations. The company intends to seek, investigate, and if warranted, acquire an interest in one or more business ventures. Previously, it offered consulting and professional services comprising technology transformation, business continuity, and disaster recovery planning processes and procedures. The company is headquartered in Boca Raton, Florida.
No recent news for Veracity Management Global, Inc. (OTCBB: VCMG).
BERGIO INTERNATIONAL INCORPORATED (OTCBB: BRGO)
"Up 53.85% on Thursday"
Detailed Quote: www.otcpicks.com/quotes/BRGO.php
Bergio International, Inc. a leading jeweler creating a diversified jewelry designer and manufacturer through acquisitions and consolidation in the estimated $160 billion a year highly fragmented independently owned jewelry industry Bergio currently sells its jewelry to approximately 50 jewelry retailers across the United States. Bergio has manufacturing control over its line through its manufacturing facility in New Jersey, as well as subcontracts with facilities in the United States and Italy.
July 18 - Bergio International Partners With Major U.S. Retail Chain
Bergio International, Inc. (OTCBB: BRGO) ("Bergio" or the "Company") announced today their first major partnership with a large U.S. retail chain with over 140 stores nationwide.
Berge Abajian, CEO of Bergio, stated, "We've been working on this partnership for the past 6 months and today I would like to announce that we will be launching the Bergio Brand in over 30 stores across the U.S. Our initial confirmed order is approximately $600,000."
He continued, "In October, when the brand is launched, a PR will be issued announcing the name of the chain." He also added, regarding the 2nd quarter results, "Preliminary indicators are showing positive 2nd quarter figures."
TORM A/S (NASDAQ: TRMD)
"Up 38.15% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/TORM.php
TORM is one of the world's leading carriers of refined oil products as well as a significant player in the dry bulk market. The Company runs a fleet of approximately 140 modern vessels in cooperation with other respected shipping companies sharing TORM's commitment to safety, environmental responsibility and customer service. TORM was founded in 1889. The Company conducts business worldwide and is headquartered in Copenhagen, Denmark.
July 19 - Articles in Today's Danish Media
With reference to certain articles in the Danish media today, TORM would like to reiterate that negotiations are still proceeding with relevant stakeholders regarding a long-term, financial solution. The content of the negotiations is in line with the main principles communicated at the Annual General Meeting on 23 April 2012 (company announcement no. 20 dated 23 April 2012). TORM will make a company announcement upon reaching an agreement.
PSIVIDA CORPORATION (NASDAQ: PSDV)
"Up 28.04% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/PSDV.php
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. ILUVIEN® for the treatment of Diabetic Macular Edema (DME), which is licensed to Alimera Sciences, Inc., is pSivida’s most advanced product candidate. It has received marketing authorization for chronic DME considered insufficiently responsive to available therapies in the UK, Austria, France and Portugal following a positive review by Austria, France, German, Italy, Portugal, Spain and the UK under the Decentralized Procedure. Marketing authorization in the remaining countries is anticipated in the coming months. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular hypertension. pSivida’s two FDA-approved products, Retisert® and Vitrasert®, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.
July 18 - pSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Security Agency of Medicines and Health Products (L’Agence Nationale de Sécurité du Médicament et des Produits de Santé) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
This marketing authorization follows the completion of the Decentralized Regulatory Procedure (DCP) in the European Union (EU), in which the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, serving as the Reference Member State (RMS), delivered a positive outcome for ILUVIEN along with six Concerned Members States (CMS), specifically Austria, France, Germany, Italy, Portugal and Spain. The French authorization is the fourth national approval in the EU, preceded by Austria, Portugal and the UK.
“We are pleased our product has received marketing authorization in France. We now have marketing authorization in four of the seven targeted EU countries,” said Dr. Paul Ashton, president and chief executive officer of pSivida. “We look forward to ILUVIEN receiving approval in the three remaining CMS countries, Germany, Italy and Spain, in the coming months.”
The International Diabetes Federation estimates that more than 4,300,000 people are currently living with diabetes in France, and according to Alimera’s estimates, more than 220,500 people suffer from vision loss associated with DME.
ILUVIEN is an injectable, sustained-release intravitreal insert that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. pSivida is developing an insert of the same design for the treatment of uveitis affecting the posterior of the eye.
IDO SECURITY INCORPORATED (OTCBB: IDOI)
"Up 45.68% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/IDOI.php
Headquartered in New York with a subsidiary in Israel, IDO Security designs, develops and markets the patented MagShoe™ shoe scanning device (SSD), filling a critical void in today's detectors by extending screening to the lower body and feet. MagShoe™'s "shoes-on" design maximizes security, thoroughness and accuracy while eliminating the need to remove shoes for increased convenience and safety; neither invasive nor harmful to the body as some of the other screening devices currently used in the marketplace. Ideal for security and loss prevention at virtually any facility, MagShoe™ is currently in use worldwide at international airports, cruise lines, government agencies, correctional facilities, mints and more.
July 2 - IDO Security Resumes Full DTC Eligibility
DTC Chill Order Removed
IDO Security Inc. (IDOI), developer of the innovative MagShoe™ shoe scanning device (SSD), announced that the Depository Trust Company (DTC), has removed the "chill" status from IDO's stock. Effective June 29, 2012, the DTC restored electronic clearance and settlement services for the Company's "IDOI" security, enabling normal electronic trading of the shares. The Depository Trust Company is a member of the U.S. Federal Reserve System and a registered clearing agency with the Securities and Exchange Commission. It was established to provide a safe and efficient way for buyers and sellers of securities to execute and settle transactions.
"We are gratified that our stock is once again DTC eligible, which will now enable our stock to be traded freely among shareholders and the investment community in the market," commented Michael Goldberg, President of IDO Security. "We continue to make strides in improving the Company's capital structure and we look to a better and brighter future in building shareholder value as our flagship product, the MagShoe, continues to expand its market presence around the world."